Sydney Lupkin
👤 SpeakerAppearances Over Time
Podcast Appearances
Although most people taking these drugs say they have some insurance coverage for them, more than half say the drugs are difficult to afford.
KFF conducted the poll between October 27th and November 2nd.
black box warnings on hormone therapies are the FDA's strongest.
They're used to inform doctors and patients that a drug can cause serious or life-threatening side effects.
The warnings had been on hormone therapies for more than 20 years and say the drugs increased the risk of certain cancers, strokes, and heart attacks.
Now the FDA is removing the warnings, saying those risks were overstated.
It's a change many doctors have urged the FDA to make, but they say the agency didn't follow its usual procedure for doing so.
The FDA convened a special expert panel in July instead of using an existing advisory committee, which follows a stricter process for reviewing evidence and making recommendations.
Black box warnings on hormone therapies are the FDA's strongest.
They're used to inform doctors and patients that a drug can cause serious or life-threatening side effects.
The warnings had been on hormone therapies for more than 20 years and say the drugs increased the risk of certain cancers, strokes, and heart attacks.
Now the FDA is removing the warnings, saying those risks were overstated.
It's a change many doctors have urged the FDA to make, but they say the agency didn't follow its usual procedure for doing so.
The FDA convened a special expert panel in July instead of using an existing advisory committee, which follows a stricter process for reviewing evidence and making recommendations.
The centerpiece of the deals is blockbuster drugs for type 2 diabetes and obesity, so Ozempic, Wegovi, Manjaro, and Zetbound.
It expands coverage to some but not all Medicare beneficiaries with obesity.
They have to have additional health conditions or a body mass index over 35.